Replying to @Dr_AmerZeidan @Papa_Heme
15-20% appears to be over simplification. HCT-CI, CHARM scores can provide better estimate & discussions. 15-20% can be higher for healthy patient with no comorbdities and lower for patient with poor PS and comorbidities. I plug in best case scenario to CHARM & TRM < than 10%.
2
1
126
Replying to @Dr_AmerZeidan
seems clearly refractory to aza-ven the way blast count is rising. Day 11, WBC count is 3.1 in blood and absolute blast count is 2.6. would you agree, clear progression? no bone marrow done. Ven is 100, due to posa.
152
Insightful talk by @DholariaMD on
allogeneic transplant outcomes in
chronic neutrophilic leukemia
from @CIBMTR @TheEBMT
showing favorable outcome
➡️N 29 (excluded blastic phase)
➡️CSF3R (n =9), ASXL1 (n=4)
➡️1 yr NRM 10%
➡️1 yr OS 69%, 4yr 55%
#DAVAWhistler
@DAVAOnc #BMTsm
Insightful talk on #HLH after #CARTsm by Dr. Pullarkat @DAVAONC #DAVAWhistler
1️⃣dropping CRP after giving tocilizumab and rising ferritin useful finding to suspect HLH #pearl
2️⃣etoposide is not recommended as it can decrease the efficacy
timing lymphodepletion in dialysis patients before CART therapy #CARTsm #onconephrology @DAVAOnc @Dr_AdrianaRossi #DAVAWhistler
1️⃣ chemo dose-adjusted for ESRD (e.g., flu 20 mg/m2 instead of 30 on days -5,-4,-3)
2️⃣ dialysis 12 h after each dose of chemo
3️⃣ N=2
PMID 35227310
Replying to @DAielloMD
let's say you started chemo-IO and the MET exon result came back later, most oncologist would continue with chemo-IO or switch to capmatinib? I am seeing many "OR" in NCCN guidelines. attaching a screenshot here. @dipeshuprety4

















